In this episode, I dive into the latest research comparing two major weight loss medications, Wegovy (semaglutide) and Zepbound (tirzepatide), based on findings from the 72-week SURMOUNT-5 trial. I explain how Zepbound led to greater weight loss (about 20.2% vs. 13.7% with Wegovy), possibly due to its dual action on GIP and GLP-1 receptors. Both drugs were generally well tolerated, with similar side effects like nausea and constipation, though Wegovy had slightly more people stop due to GI issues. I also emphasize that while Zepbound may appear more effective, individual needs, such as cardiovascular health or sleep apnea, should guide treatment decisions. Lastly, I remind you that sustainable weight loss requires patience, realistic expectations, and a holistic approach that includes lifestyle changes, not just medication.
============================
FOLLOW ME 👇
Facebook: https://www.facebook.com/drshellymd
Instagram: https://www.instagram.com/drshellymd/
Twitter: https://twitter.com/drshellymd
LinkedIn: https://www.linkedin.com/in/drshellymd/
Website: https://drshellymd.com/
Podcast: https://drshellymd.com/podcast/
============================